相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
Alberto Zaniboni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Uwe Pelzer et al.
EUROPEAN JOURNAL OF CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
Elias Assaf et al.
ONCOLOGY (2011)
Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma A Multicenter Experience of the Gruppo Oncologico Italia Meridionale
Vittorio Gebbia et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
Andrew H. Ko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer
Sung Yong Oh et al.
INVESTIGATIONAL NEW DRUGS (2010)
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
Eileen M. O'Reilly et al.
ONCOLOGIST (2010)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C. Yoo et al.
BRITISH JOURNAL OF CANCER (2009)
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: Results of a phase II study
Andrew H. Ko et al.
CANCER INVESTIGATION (2008)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
S. Boeck et al.
ANNALS OF ONCOLOGY (2007)
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients
HA Burris et al.
ONCOLOGIST (2005)
分享论文
